Eleven Biotherapeutics Shifts Focus After Trial Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Absorbing a 69% stock price crash after the failure of its pivotal trial of EBI-005 in dry-eye disease, Eleven Biotherapeutics explains why it still has faith in other ocular indications and candidates.